To say this has been a big year for Summit Therapeutics (NASDAQ: SMMT) would be a huge understatement. The stock has risen ...

Devoid of any marketed drug in its portfolio, investors will likely focus on SMMT's pipeline updates when it reports third-quarter results this month.

Bob Duggan, chairman and co-CEO of Summit Therapeutics Inc. (NASDAQ:SMMT), is capitalizing on a remarkable 689% stock surge ...

Presentations will summarize new preclinical data from brain-penetrant, pan-mutant B-Raf degrader program and recent clinical ...

The company provided clear evidence that it has plenty of resources to continue developing a potential blockbuster drug.

Earlier this year, Eshelman Innovation and the North Carolina Biotechnology Center hosted the 2024 N.C. Radiopharmaceuticals ...

Citi analyst Yigal Nochomovitz has reiterated their bullish stance on RCUS stock, giving a Buy rating on October 21. Yigal Nochomovitz’s ...

Fundraising has slowed and valuations are down, but biotech founders could have a lifeline in family office investments, ...

In a report released today, Ami Fadia from Needham maintained a Buy rating on Cogent Biosciences (COGT – Research Report), with a price ...

The session will highlight latest developments in the company’s protein homeostasis program as BPGbio continues to advance ...

Cancer Research UK, one of the world's largest funders of cancer research, and KisoJi Biotechnology Inc., a company focussed on the discovery and development of antibody therapeutics, have signed a ...

Qurient Co. Ltd. (KRX: 115180) has announced the commencement of a clinical trial for adrixetinib (formerly named Q702), following the clearance of its investigational new drug (IND) application by ...